Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 14, 2013; 19(42): 7316-7326
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7316
Published online Nov 14, 2013. doi: 10.3748/wjg.v19.i42.7316
Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update
Marco Vivarelli, Roberto Montalti, Hepatobiliary and Abdominal Transplantation Surgery, Department of Gastroenterology and Transplantation, Polytechnic University of Marche, 60129 Ancona, Italy
Andrea Risaliti, Department of Surgery and Transplantation, University of Udine, 33100 Udine, Italy
Author contributions: Vivarelli M conceived and designed the study; Montalti R drafted the article and acquired, analyzed and interpreted the data; Risaliti A revised the manuscript.
Correspondence to: Marco Vivarelli, MD, Hepatobiliary and Abdominal Transplantation Surgery, Department of Gastroenterology and Transplantation, Polytechnic University of Marche, A.O.U. “Ospedali Riuniti”, Via Conca 71, 60129 Ancona, Italy. vivarelli63@libero.it
Telephone: +39-71-5965099 Fax: +39-71-5965100
Received: July 3, 2013
Revised: August 8, 2013
Accepted: September 16, 2013
Published online: November 14, 2013
Revised: August 8, 2013
Accepted: September 16, 2013
Published online: November 14, 2013
Core Tip
Core tip: Hepatocellular carcinoma (HCC) occurs frequently, and its association with cirrhosis makes treatment complex and challenging. The treatment of HCC must take into account the presence and stage of chronic liver disease with the aim of preserving hepatic function that is often already impaired. The different treatment options include surgical resection, transplantation, local ablation, chemoembolization, radioembolization and molecular targeted therapies. Downstaging and bridging are different strategies for the management of HCC patients who will undergo liver transplantation. The purpose of this review is to provide a comprehensive description of the current treatment options for patients with HCC.